International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
Clinical Infectious Diseases · 17.03.2026 · 82 (3) · e446-e454
DOI: 10.1093/cid/ciaf606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.11.2025. Verfasst von Safia Kuriakose und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
In December 2021 and January 2022, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug, nirmatrelvir/ritonavir, was authorized in the United States, Canada, and Europe. However, ritonavir has significant drug-drug interaction (DDI) potential, and information resources were incomplete or provided conflicting advice for certain DDIs. Within the challenging pandemic setting, nirmatrelvir/ritonavir was being prescribed largely by clinicians unfamiliar with ritonavir. Coronavirus disease 2019 (COVID-19) affects people with comorbid conditions and polypharmacy who could benefit from therapy, but prescriber uncertainty surrounding the appropriate management of DDIs was a barrier to the use of nirmatrelvir/ritonavir. To support clinicians, the National Institutes of Health (NIH) panel on COVID-19 guidelines, the Ontario COVID-19 Science Advisory Table, and the University of Liverpool independently developed prescribing guidelines. Ultimately, the groups united to establish the LiON-PK (Liverpool-Ontario-NIH Pharmacokinetics) collaboration. Here we describe how the team developed pragmatic and harmonized guidance for managing DDIs with nirmatrelvir/ritonavir. This framework may inform development of prescribing resources for other complex medications or for future pandemic preparedness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
- Toronto General Hospital, University Health Network and Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
- Division of Antivirals, Office of Infectious Diseases, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
- Centre for Experimental Therapeutics, University of Liverpool, Liverpool, United Kingdom.
- Infection and Immunology Clinic, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
- Health, People and Human Services Group, ICF, Reston, Virginia, USA.
ORCID-Profile: Safia Kuriakose, Alice Tseng, Justin Chiong, Fiona Marra, Alison Boyle, Tessa Senneker, Claire Lund, Pamela Belperio, Page Crew, Greg Eschenauer, Kimberly K Scarsi, Catia Marzolini
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Kuriakose, S., Tseng, A., Boyd, S., Gibbons, S., Chiong, J., Marra, F., Boyle, A., Senneker, T., George, J., Lund, C., Belperio, P., Crew, P., Eschenauer, G., Scarsi, K. K., Khoo, S. H., Pau, A., Marzolini, C., & LiON-PK collaboration (2026). International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. Clinical Infectious Diseases, 82(3), e446-e454. https://doi.org/10.1093/cid/ciaf606
Vancouver
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, et al. International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. Clinical Infectious Diseases. 2026;82(3):e446-e454. doi:10.1093/cid/ciaf606
BibTeX
@article{Kuriakose2026,
author = {Kuriakose, Safia and Tseng, Alice and Boyd, Sarita and Gibbons, Sara and Chiong, Justin and Marra, Fiona and Boyle, Alison and Senneker, Tessa and George, Jomy and Lund, Claire and Belperio, Pamela and Crew, Page and Eschenauer, Greg and Scarsi, Kimberly K and Khoo, Saye H and Pau, Alice and Marzolini, Catia and LiON-PK collaboration, LiON-PK collaboration},
title = {International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {3},
pages = {e446--e454},
doi = {10.1093/cid/ciaf606}
}
EUVIMED